ZURICH, May 13 (Reuters): Novartis said on Monday claims of price fixing against its Sandoz generics unit amid a US probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit filed last week.
"We believe that these claims are without merit and will vigorously contest them," Novartis said. "Sandoz takes its obligations under the antitrust laws seriously.
Novartis vows to fight US price-fixing claims
FE Team | Published: May 13, 2019 23:28:27
Novartis vows to fight US price-fixing claims
Share if you like